INVO Fertility, Inc. announced its Q3 2025 financial results, with revenue at $1,757,094, a 23% increase from the previous year. Clinic revenue from Atlanta and Wisconsin increased 21% to $1,722,223. The net loss was $(2.6) million, and Adjusted EBITDA was $(947,568). The company saw 23% organic growth and a 130% increase in INVOcell device revenue.

The Company’s Q3 2025 operational highlights include a focus on organic clinic growth, acquisition strategy, and INVOcell device expansion. The U.S. Departments announced new policy updates allowing employers to offer standalone infertility benefits, expanding access to IVF coverage. Operational efficiencies were improved through a strategic partnership with Heidi Health and initiatives for enhanced profitability.

INVO Fertility CEO Steve Shum commented on the quarter’s progress, highlighting an 18% organic growth across clinics driven by increased patient volume and marketing efforts. The company is pursuing strategic initiatives to scale the business, with ongoing acquisition efforts and a pipeline of target clinics. INVOcell device expansion initiatives delivered 130% growth in device revenue.

Adjusted EBITDA is a non-GAAP measure used to provide meaningful information related to the company’s operating performance and liquidity. It has been included in the financial results to enhance an overall understanding of financial trends. The reconciliation of Adjusted EBITDA can be found in the Company’s Form 10-Q on their website or the SEC’s website.

INVO Fertility, Inc. is a healthcare services company focused on expanding access to assisted reproductive technology. Their commercial strategy includes building, acquiring, and operating fertility clinics, offering INVOcell technology for IVC procedures and IVF clinics. INVOcell is a proprietary device allowing fertilization and early embryo development in vivo, providing a more connected and affordable ART treatment.

Read more at GlobeNewswire: INVO Fertility Announces Third Quarter 2025 Financial